SEC Form 4 · accession 0001123292-18-001115
Arbutus Biopharma Corp · ABUS
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Koert VandenEnden
Officer — Chief Accounting Officer
Period of report
Dec 11, 2018
Accepted (ET)
Dec 13, 2018 · 3:11 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001447028
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (Right to Buy)F1 | $4.44 | Dec 11, 2018 | A | 7,500 | A | — | Dec 11, 2028 | Common Shares | 7,500 | 7,500 | D |
Explanation of responses
- F1The option will vest on termination of employment.